Loss of TGF-beta growth inhibition is a hallmark of many human tumors. The TGF-beta signaling pathway involves the activation of anaphase-promoting complex (APC), a multisubunit ubiquitin protein ligase, which in turn facilitates the destruction of SnoN, a transcriptional co-suppressor, thereby mediating the transactivation of TGF-beta responsive genes responsible for cell cycle arrest. APC appears to act in conjunction with other moieties, including Cdh1 and Smad2/Smad3, but the mechanism by which it is activated by TGF-beta signaling is poorly understood. The objectives of the current proposal are to elucidate that mechanism and further validate the role of TGF-beta activated APC in suppressing tumor formation using human, breast tumor xenografts in a mouse model. We have recently obtained evidence implicating the phosphorylation of Cdc27, a key subunit of APC, in the process of activation, as well as evidence suggesting that the responsible enzyme may be casein kinase II. Based on these and other data, we hypothesize that TGF-beta activates APC through a process that involves Cdc27 phosphorylation and Smad2/Smad3 recruitment of Cdh1.
Our specific aims will be (1) to identify the kinase responsible for phosphorylation of Cdc27 by confirming the role of casein kinase II and/or determining a role for other candidate kinases; (2) to characterize the nature of the interactions between the kinase and APC and their biological consequences (SnoN destruction and cell cycle arrest); and (3) to validate the role of activation of APC by TGFbeta in suppressing tumor progression in a human, breast tumor xenograft mouse model. Understanding the biological mechanisms involved in TGF-beta signaling via APC and validating the role of APC as a TGF-beta effecter in the inhibition of breast tumor progression will be important for future studies that seek to determine how impaired signaling contributes to oncogenesis and for identification of potential targets for therapeutic intervention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA115943-02
Application #
7105449
Study Section
Tumor Cell Biology Study Section (TCB)
Program Officer
Blair, Donald G
Project Start
2005-09-01
Project End
2010-06-30
Budget Start
2006-07-31
Budget End
2007-06-30
Support Year
2
Fiscal Year
2006
Total Cost
$229,116
Indirect Cost
Name
University of Pittsburgh
Department
Physiology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Hu, Dong; Zhou, Zhuan; Davidson, Nancy E et al. (2012) Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis. J Biol Chem 287:13584-97
Gamper, Armin M; Qiao, Xinxian; Kim, Jennifer et al. (2012) Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis. Mol Cell 45:233-43
Hu, Dong; Wan, Yong (2011) Regulation of Krüppel-like factor 4 by the anaphase promoting complex pathway is involved in TGF-beta signaling. J Biol Chem 286:6890-901
Zhang, Liyong; Fujita, Takeo; Wu, George et al. (2011) Phosphorylation of the anaphase-promoting complex/Cdc27 is involved in TGF-beta signaling. J Biol Chem 286:10041-50
Hu, Dong; Liu, Weijun; Wu, George et al. (2011) Nuclear translocation of Skp2 facilitates its destruction in response to TGF? signaling. Cell Cycle 10:285-92
Hu, Dong; Qiao, Xinxian; Wu, George et al. (2011) The emerging role of APC/CCdh1 in development. Semin Cell Dev Biol 22:579-85
Liu, Weijun; Zong, Wenjun; Wu, George et al. (2010) Turnover of BRCA1 involves in radiation-induced apoptosis. PLoS One 5:e14484
Zhang, Liyong; Park, Chi-Hoon; Wu, Jing et al. (2010) Proteolysis of Rad17 by Cdh1/APC regulates checkpoint termination and recovery from genotoxic stress. EMBO J 29:1726-37
Qiao, Xinxian; Zhang, Liyong; Gamper, Armin M et al. (2010) APC/C-Cdh1: from cell cycle to cellular differentiation and genomic integrity. Cell Cycle 9:3904-12
Fujita, Takeo; Liu, Weijun; Doihara, Hiroyoshi et al. (2009) An in vivo study of Cdh1/APC in breast cancer formation. Int J Cancer 125:826-36

Showing the most recent 10 out of 17 publications